omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza]
omega-3
RxCUI: 607044
What the CMS Formulary Data Shows for omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza]
Per the CMS 2026 Part D formulary file, omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza] (RxNorm concept RXCUI 607044, generic name omega-3) appears on 1 distinct formulary file spanning 1 Medicare Part D plan offering - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.
Real-world access to omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 223,941 Part D beneficiaries filled omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza] in 2023, with total plan-and-beneficiary spending of $78,407,827 and an average per-beneficiary annual cost of $350.13. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 1
- Coverage rate
- 0%
- Tier range
- Tier 1, Preferred Generic
- Average tier
- Tier 1, Preferred Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 223,941
- Total spending
- $78,407,827
- Avg per beneficiary
- $350.13
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza]
1 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| CareAdvantage (HMO D-SNP) | SAN MATEO HEALTH COMMISSION | T1 | No | $0 | CA |
Frequently Asked Questions
Is omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza] covered by Medicare Part D?
Yes, omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza] is covered by 1 Medicare Part D plans (0% of all Part D formularies).
What tier is omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza] on Medicare Part D plans?
omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.
Does omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza] require prior authorization?
0% of Part D formularies require prior authorization for omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza]?
In 2023, total Medicare Part D spending on omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule [Lovaza] was $78,407,827, covering 223,941 beneficiaries. The average spend per beneficiary was $350.13.
Read our methodology - how this data is sourced, computed, and verified.